Zobrazeno 1 - 10 of 74 pro vyhledávání: '"Karina J Yoon"'
1
Akademický článek
EZH2 inhibition decreases neuroblastoma proliferation and in vivo tumor growth.
Autor: Laura V Bownes, Adele P Williams, Raoud Marayati, Laura L Stafman, Hooper Markert, Colin H Quinn, Nikita Wadhwani, Jamie M Aye, Jerry E Stewart, Karina J Yoon, Elizabeth Mroczek-Musulman, Elizabeth A Beierle
Publikováno v: PLoS ONE, Vol 16, Iss 3, p e0246244 (2021)
Investigation of the mechanisms responsible for aggressive neuroblastoma and its poor prognosis is critical to identify novel therapeutic targets and improve survival. Enhancer of Zeste Homolog 2 (EZH2) is known to play a key role in supporting the m
Externí odkaz: https://doaj.org/article/00f6cc5570544d52be7e472249944929
Zobrazit plný text záznamu
2
Akademický článek
Preclinical evidence for employing MEK inhibition in NRAS mutated pediatric gastroenteropancreatic neuroendocrine-like tumors
Autor: Colin H. Quinn, Andee M. Beierle, Adele P. Williams, Raoud Marayati, Laura V. Bownes, Hooper R. Market, Michael E. Erwin, Jamie M. Aye, Jerry E. Stewart, Elizabeth Mroczek-Musulman, Karina J. Yoon, Elizabeth A. Beierle
Publikováno v: Translational Oncology, Vol 47, Iss , Pp 102045- (2024)
Background: Pediatric gastroenteropancreatic neuroendocrine tumors are exceedingly rare, resulting in most pediatric treatment recommendations being based on data derived from adults. Trametinib is a kinase inhibitor that targets MEK1/2 and has been
Externí odkaz: https://doaj.org/article/0515712cdd0f4633a52a9cf06e81c2dc
Zobrazit plný text záznamu
3
Akademický článek
Development and histopathological characterization of tumorgraft models of pancreatic ductal adenocarcinoma.
Autor: Patrick L Garcia, Leona N Council, John D Christein, J Pablo Arnoletti, Marty J Heslin, Tracy L Gamblin, Joseph H Richardson, Mary-Ann Bjornsti, Karina J Yoon
Publikováno v: PLoS ONE, Vol 8, Iss 10, p e78183 (2013)
Pancreatic cancer is the one of the deadliest of all malignancies. The five year survival rate for patients with this disease is 3-5%. Thus, there is a compelling need for novel therapeutic strategies to improve the clinical outcome for patients with
Externí odkaz: https://doaj.org/article/1b49cc214efe4869a754ebeb935861fe
Zobrazit plný text záznamu
6
Akademický článek
The BET inhibitor JQ1 attenuates double-strand break repair and sensitizes models of pancreatic ductal adenocarcinoma to PARP inhibitorsResearch in context
Autor: Aubrey L. Miller, Samuel C. Fehling, Patrick L. Garcia, Tracy L. Gamblin, Leona N. Council, Robert C.A.M. van Waardenburg, Eddy S. Yang, James E. Bradner, Karina J. Yoon
Publikováno v: EBioMedicine, Vol 44, Iss , Pp 419-430 (2019)
Background: DNA repair deficiency accumulates DNA damage and sensitizes tumor cells to PARP inhibitors (PARPi). Based on our observation that the BET inhibitor JQ1 increases levels of DNA damage, we evaluated the efficacy of JQ1 + the PARPi olaparib
Externí odkaz: https://doaj.org/article/06329e4890dc457f95f1890ebe29c231
Zobrazit plný text záznamu
7
Akademický článek
Targeting PIM Kinases Affects Maintenance of CD133 Tumor Cell Population in Hepatoblastoma
Autor: Laura L. Stafman, Adele P. Williams, Evan F. Garner, Jamie M. Aye, Jerry E. Stewart, Karina J. Yoon, Kimberly Whelan, Elizabeth A. Beierle
Publikováno v: Translational Oncology, Vol 12, Iss 2, Pp 200-208 (2019)
Hepatoblastoma is the most common primary liver tumor in children, but treatment has not changed significantly in the past 20 years. We have previously demonstrated that Proviral Integration site for Moloney murine leukemia (PIM) kinases promote tumo
Externí odkaz: https://doaj.org/article/50eba423670a4f4380c1edd4eb9fdaa0
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje